Clinical Evaluation of Safety and Efficacy of Nepafenac Ophthalmic Suspension, 0.1% Compared to Placebo for the Prevention and Treatment of Ocular Inflammation and Pain Associated With Cataract Surgery in Adult Chinese Subjects.

Trial Profile

Clinical Evaluation of Safety and Efficacy of Nepafenac Ophthalmic Suspension, 0.1% Compared to Placebo for the Prevention and Treatment of Ocular Inflammation and Pain Associated With Cataract Surgery in Adult Chinese Subjects.

Completed
Phase of Trial: Phase III

Latest Information Update: 10 May 2013

At a glance

  • Drugs Nepafenac (Primary)
  • Indications Postoperative pain
  • Focus Registrational; Therapeutic Use
  • Most Recent Events

    • 18 May 2012 Actual patient number added 260 according to ClinicalTrials.gov.
    • 18 May 2012 Actual end date (Apr 2012) added as reported by ClinicalTrials.gov.
    • 18 May 2012 Status changed from recruiting to completed as reported by ClinicalTrials.gov.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top